Eli Lilly

TransCelerate selects Cognizant to develop subscription-based, clinical trials collaboration platform

Friday, July 25, 2014 12:54 PM

TransCelerate BioPharma has selected Cognizant to develop a first-of-its-kind, subscription-based platform to transform the way clinical sites collaborate with pharmaceutical companies on clinical trials.

More... »

WIRB Copernicus Group

ABPI establishes Inward Investor Group

Wednesday, July 23, 2014 10:45 AM

The Association of the British Pharmaceutical Industry (ABPI) has established a new Inward Investor Group to demonstrate the importance of inward investment to the U.K. and the global mobility of such investment. The group also will work toward cultivating a favorable environment for pharmaceutical companies to invest in the U.K.

More... »

CRF Health eCOA webinar series

Seven pharma companies offer deprioritized compounds for re-purposing

Wednesday, July 23, 2014 10:15 AM

U.K. researchers will be granted access to a ‘virtual library’ of deprioritized pharmaceutical compounds through a new partnership between the Medical Research Council (MRC) and seven global drug companies.

More... »

Alzheimer's disease market forecast to reach nearly $12B by 2023

Monday, July 21, 2014 03:29 PM

Decision Resources Group has found the market for Alzheimer's disease (AD) therapies will more than triple, reaching nearly $12 billion by 2023, largely due to the forecasted launch of the first disease-modifying therapies (DMTs), a landmark event in AD treatment.

More... »

Eli Lilly, Immunocore collaborate for novel cancer therapies

Wednesday, July 16, 2014 01:15 PM

Eli Lilly and Immunocore, a privately owned, clinical-stage biotechnology company, have entered into a co-discovery and co-development collaboration to research and potentially develop novel T cell-based cancer therapies.

More... »

OptiNose adds three to operations, regulatory affairs and commercialization

Thursday, June 12, 2014 12:34 PM

OptiNose, a global specialty pharmaceuticals company, has announced three appointments to the company's senior management team.

More... »

Lilly's CYRAMZA (ramucirumab) produces positive phase III results

Friday, June 6, 2014 01:46 PM

Eli Lilly has announced detailed results from REVEL, a global phase III study of CYRAMZA (ramucirumab) in combination with chemotherapy in patients with second-line non-small cell lung cancer (NSCLC). REVEL is the first positive phase III study of a biologic in combination with chemotherapy to demonstrate improved overall survival compared to chemotherapy alone in second-line NSCLC.

More... »

Certara names Dr. Edmundo Muniz new CEO

Thursday, June 5, 2014 08:05 AM

Certara, a global technology-enabled drug development and drug safety consultancy, has appointed Dr. Edmundo Muniz its new chief executive officer.

More... »

Qiagen, Eli Lilly collaborate to co-develop companion diagnostics

Tuesday, June 3, 2014 11:17 AM

Qiagen, a Netherlands-based holding company, is collaborating with Eli Lilly to co-develop universal and modular assay panels for the simultaneous analysis of DNA and RNA biomarkers targeting multiple cellular pathways involved in common cancer types. The agreement includes the development of tests that will be based on Qiagen's multi-modal, multi-analyte Modaplex analysis platform, which can process multiple sample types and biomarkers in a single test.   

More... »

Eli Lilly increases access to clinical trials data for qualified researchers

Monday, June 2, 2014 01:10 PM

Eli Lilly will begin sharing its clinical trial data with scientific researchers through www.clinicalstudydatarequest.com. This web site, which houses data from several trial sponsors, was created in support of ongoing efforts by the Pharmaceutical Research and Manufacturers of America (PhRMA) and the European Federation of Pharmaceutical Industries and Associations (EFPIA) to increase access to and transparency of clinical trial results with researchers around the world.

More... »

CenterWatch Data Library
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

July 21

As job growth in drug development sector soars, more employees are seeking new opportunities

U.K. study: Prisoners should have the right to participatein clinical trials on moral grounds, for healthcare access

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

July

IRB market consolidating rapidly
Private equity driving a new commercial ethical review landscape

Lessons learned from medical device trials
Smaller, faster, more flexible trials hold important insights for pharmaceutical innovation

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

June

CRO market poised for growth and consolidation
Sponsors expanding pipelines, shrinking infrastructure fuel strategic outsourcing

Strategies for success evolving in phase I space
Sites see increasing complexity, more patients, greater focus on efficacy

Already a subscriber?
Log in to your digital subscription.

Purchase the June issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs